The cytokine TGF-β triggers cancer cells to become more migratory, invasive, and resistant to chemotherapy. We discovered that a TGF-β–induced long non-coding RNA (lncRNA) called LIMD1-AS1 enhances the SMAD protein response and cancer cell plasticity. LIMD1-AS1 stimulates the formation of a complex between the intracellular TGF-β effector SMAD3 and the transcriptional co-activator p300 by directly interacting with both factors.
Our study identifies LIMD1-AS1 as a new enhancer of TGF-β signaling, suggesting it could be a potential therapeutic target for breast cancer treatment.
If you’d like to know more, please read our Nucleic Acids Research paper: https://academic.oup.com/nar/article/53/16/gkaf841/8245226
Looking for information on one of our topics, a new place to conduct your research or experienced research to join forces with? Feel free to contact us.!